Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI)

Category Primary study
JournalJournal of Clinical Oncology
Year 2010
This article has no abstract
Epistemonikos ID: 497ec468ad13d866c08863869765dd495da2f780
First added on: Mar 01, 2025